-
Bristol Myers Squibb
-
Sector
Health Care
-
Industry
Pharmaceuticals
-
Company web
Link
-
Employees
Full Time Employees: 25,000
-
Executives
- Giovanni Caforio
- Charles Bancroft
- Louis Schmukler
- Ann Judge
- Thomas Lynch
- Sandra Leung
- Murdo Gordon
- Paul von Autenried
- Anne Nielsen
- Joseph Caldarella
-
Company address
- 345 Park Avenue
- New York, NY 10154
- United States of America
- 1-212-546-4000
-
Investor Relation Site
Link
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company’s products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaboration agreements with Portola Pharmaceuticals, Inc., Apexigen, Inc., and Nordic Bioscience; clinical research collaborations with Array BioPharma, Novartis, Clovis Oncology, Inc., and Daiichi Sankyo; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Bristol Myers Squibb: Slide deck
- BMY - Q3 Earning Release Presentation 26 Oct 2017: Slides deck
- BMY - Q2 Earning Release Presentation 27 July 2017: Slides deck
- BMY - Q1 Earning Release Presentation 27 April 2017: Slides deck
- BMY - Q4 Earning Release Presentation 26 Jan 2017: Slides deck
- BMY - Q3 Earning Release Presentation 27 Oct 2016: Slides deck
- BMY - Q2 Earning Release Presentation 28 July 2016: Slides deck
- BMY - Q1 Earning Release Presentation 28 April 2016: Slides deck